According to Lee Cheng-chia, chairman of Phytohealth, the many variables involved in undertaking biotechnology research from scratch make this approach unfeasible for Taiwan.
「完全原創型的生物科技研發，不定數太高，」懷特新藥董事長李成家在一次研討會上，點出台灣的先天侷限。